- Home
- CANF vs OVBC Comparison
CANF vs OVBC Comparison
Compare CANF & OVBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- OVBC
- Stock Information
- Founded
- CANF 1994
- OVBC 1872
- Country
- CANF Israel
- OVBC United States
- Employees
- CANF N/A
- OVBC N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- OVBC Major Banks
- Sector
- CANF Health Care
- OVBC Finance
- Exchange
- CANF Nasdaq
- OVBC Nasdaq
- Market Cap
- CANF 13.5M
- OVBC 149.1M
- IPO Year
- CANF N/A
- OVBC N/A
- Fundamental
- Price
- CANF $1.03
- OVBC $34.50
- Analyst Decision
- CANF Strong Buy
- OVBC
- Analyst Count
- CANF 2
- OVBC 0
- Target Price
- CANF $14.00
- OVBC N/A
- AVG Volume (30 Days)
- CANF 83.3K
- OVBC 32.7K
- Earning Date
- CANF 08-29-2025
- OVBC 07-25-2025
- Dividend Yield
- CANF N/A
- OVBC 2.55%
- EPS Growth
- CANF N/A
- OVBC 10.90
- EPS
- CANF N/A
- OVBC 2.67
- Revenue
- CANF $674,000.00
- OVBC $61,741,000.00
- Revenue This Year
- CANF $461.72
- OVBC N/A
- Revenue Next Year
- CANF N/A
- OVBC N/A
- P/E Ratio
- CANF N/A
- OVBC $13.00
- Revenue Growth
- CANF N/A
- OVBC 10.84
- 52 Week Low
- CANF $0.98
- OVBC $21.76
- 52 Week High
- CANF $4.69
- OVBC $40.99
- Technical
- Relative Strength Index (RSI)
- CANF 42.43
- OVBC 61.96
- Support Level
- CANF $1.00
- OVBC $32.21
- Resistance Level
- CANF $1.05
- OVBC $34.50
- Average True Range (ATR)
- CANF 0.02
- OVBC 1.35
- MACD
- CANF 0.00
- OVBC 0.23
- Stochastic Oscillator
- CANF 40.00
- OVBC 92.48
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About OVBC Ohio Valley Banc Corp.
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services within Southeastern Ohio as well as western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers and other standard banking products and services.